16 December 2018
Global reach, higher impact
Int J Med Sci 2013; 10(8):988-994. doi:10.7150/ijms.5944
Lack of Association of C-Met-N375S Sequence Variant with Lung Cancer Susceptibility and Prognosis
1. Department of Chest Medicine, Chi Mei Medical Center, Tainan, Taiwan, R.O.C.;
Background: Previously, we identified a sequence variant (N375S) of c-Met gene, however, its association with lung cancer risk and prognosis remain undefined.
Patients and Methods: We investigated the genotype distribution of the c-Met-N375S sequence variant in 206 lung cancer patients and 207 non-cancer controls in the Taiwanese population by DNA sequencing.
Results: Lung cancer patients with variant A/G and G/G genotypes showed 1.08-fold increased cancer risk when compared to patients with the wild-type A/A genotype (95% CI, 0.60-1.91). There were no significant differences in postoperative survival between c-Met-N375S and wild-type patients. In the cell model, the c-Met-N375S cells showed a decrease in cell death upon treatment with MET inhibitor SU11274 compared to wild-type cells.
Conclusion: Our data suggest that the c-Met-N375S sequence variant may not play a significant role in cancer susceptibility and the prognosis of lung cancer patients. The correlation with chemoresponse of c-Met-N375S is worth further investigation in patients receiving MET therapy.
Keywords: c-Met, N375S, cancer risk, prognosis, lung cancer.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Shieh JM, Tang YA, Yang TH, Chen CY, Hsu HS, Tan YHC, Salgia R, Wang YC. Lack of Association of C-Met-N375S Sequence Variant with Lung Cancer Susceptibility and Prognosis. Int J Med Sci 2013; 10(8):988-994. doi:10.7150/ijms.5944. Available from http://www.medsci.org/v10p0988.htm